Vasopressin for Treating Vasodilatory Shock
Author Information
Author(s): Polito A, Parisini E, Ricci Z, Picardo S, Annne D
Primary Institution: Ospedale Pediatrico Bambino Gesu, Roma, Italy
Hypothesis
Does vasopressin/terlipressin reduce mortality and morbidity in patients with vasodilatory shock?
Conclusion
Vasopressin/terlipressin therapy does not significantly affect all-cause mortality in patients with vasodilatory shock.
Supporting Evidence
- Patients treated with vasopressin had a lower dosage of norepinephrine.
- There was no significant increase in adverse events between treatment and control groups.
Takeaway
This study looked at whether a medicine called vasopressin helps people who are very sick. It found that it doesn't really help them live longer, but it might help them use less of another medicine.
Methodology
The study included randomized and quasi-randomized trials comparing vasopressin/terlipressin to placebo or supportive treatment in patients with vasodilatory shock.
Limitations
The study did not demonstrate a significant effect on mortality, indicating a lack of evidence for routine use.
Participant Demographics
Adult and pediatric patients with vasodilatory shock.
Statistical Information
P-Value
0.19
Confidence Interval
95% CI, 0.81 to 1.04
Statistical Significance
p=0.19
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website